• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Arthritis News / Prevalence of Coronary Arterial Calcification in Patients with Rheumatoid Arthritis

Prevalence of Coronary Arterial Calcification in Patients with Rheumatoid Arthritis

April 13, 2005 By Arthritis Center

An increased risk of cardiovascular disease, particularly of myocardial infarction and cardiovascular death, has been identified in patients with RA. Several investigations have identified an increase in carotid artery atherosclerosis in RA patients. However, to date, no published studies have investigated coronary atherosclerosis directly. Here, Chung et al (Arthritis Rheum 2005; 52(10): 3045) investigate coronary arterial calcification (CAC) assessed by electron beam computed tomography (EBCT) in RA and non-RA patients as a measure of coronary atherosclerosis.

Methods:

Patients from the Nashville, Tennessee area with early (disease duration less than 5 years) and established (disease duration greater than 10 years) RA were recruited to undergo EBCT for determination of CAC, quantified as the Agatston score. Non-RA control subjects underwent similar testing and were group matched to the RA subjects based on age, gender, and race. Subjects with cardiac risk factors, known cardiovascular disease, and previous cardiac revascularization procedures were included.

Results:

141 RA subjects (70 with early and 71 with established RA) and 86 non-RA control subjects were enrolled. Mean age was between 51 and 58 years, with approximately two-thirds of patients being female and approximately 90% Caucasian. Despite group matching, RA subjects with established RA were significantly older than control subjects (58 vs. 51 years, respectively; p<0.001). Baseline cardiovascular risk factors (e.g. family history of cardiovascular disease, lipoprotein fractions, statin use) were balanced between established RA and control subjects, with the exception of the prevalence of hypertension (67% vs. 38%, respectively, p<0.001) and mean serum homocysteine concentration (10.8 vs. 8.2 micromol/L, respectively; p<0.001). The prevalence of current smoking was significantly higher among both RA groups compared to the control group (22.9% and 29.6% vs. 9.3%, respectively; p=0.005); however, cumulative smoking in pack years was similar between the two groups. Mean disease duration was 2 years (from first symptom of disease) for early RA subjects and 20 years for established RA subjects.

Prevalence of CAC in RA and Control Subjects

Non-Ra Control
(n=86)
Early RA
(n=70)
p Established RA
(n=71)
p
Median Agatston score 0 0 — 40.2 0.001
Prevalence with any CAC 38.4% 42.9% 0.57 60.6% 0.006
Prevalence with Agatston score 1-109 24.4% 25.7% — 19.7% —
Prevalence with Agatston score >109 13.9% 17.1% — 40.8% —

Likelihood of Severe Coronary Atherosclerosis (Agatston score > 109) in RA vs. Control Subjects

Likelihood of Agatston score >109
(unadjusted)
Likelihood of Agatston score >109
(adjusted for age and gender)
Likelihood of Agatston score >109
(adjusted for cardiovascular risk factors)
Early RA vs. control OR 1.21 (95%CI 0.65-2.26) OR 1.31 (95%CI 0.65-2.64) OR 1.44 (95%CI 0.67-3.10)
Established RA vs. control OR 3.03 (95%CI 1.65-5.57) OR 2.73 (95%CI 1.36-5.47) OR 1.31 (95%CI 1.55-7.53)

After adjusting for age and gender, only increasing pack-years of smoking and increasing ESR were significantly associated with the likelihood of having an Agatston score > 109 in RA patients (OR 1.02 per increment of 1 pack year of smoking or increment 1 mm/hr of ESR).

Conclusions:

CAC is more prevalent and more severe in RA patients with established disease compared to non-RA controls or RA patients with early disease. This increase is not explained by the prevalence of conventional risk factors. In RA patients, severe coronary atherosclerosis is significantly associated with increasing smoking and ESR.

Editorial Comment:

This is the first published investigation to demonstrate increased coronary pathology in RA and supports previous ultrasound studies of the carotid arteries to confirm an increased burden of atherosclerotic vascular disease in RA. The finding here that excess coronary calcification is a relatively late phenomenon in RA is significant, but may not necessarily indicate that coronary vascular changes are not occurring early in the RA disease process. The process of plaque calcification is complex, and may also be differentially affected in RA patients compared to controls. EBCT is only able to detect calcified, but not un-calcified plaque, which may actually be less stable than calcified plaque and more prone to rupture. Thus, if techniques to measure total atherosclerotic plaque were utilized, early RA patients might demonstrate differences from control subjects.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Recent News

Exercise Tips for Arthritis Patients

How Does Exercise Affect my Joints? How Frequently Should I Be Exercising? Should I Lose Weight for Exercise to be

Risks and Benefits of Biologic Medications

Victoria Ruffing, RN, BC, Director of Patient Education at the Johns Hopkins Arthritis Center, shares the risks and benefits of biologic for

How to Manage Rheumatoid Arthritis Flares

Through research, doctors have a clearer understanding of how flares can impact a patient on a personal and emotional level. Dr. Uzma Haque

Complementary & Alternative Medicines for Psoriatic Arthritis

There are many complementary & alternative medicines and practices that have been found to be beneficial in curbing arthritis pain,

I can’t be a runner because I have Rheumatoid Arthritis (RA), right?

Dr. Manno discusses running and Rheumatoid Arthritis. Is it an option for the RA patient?

News Categories

  • Ankylosing Spondylitis News
  • Fibromyalgia News
  • Gout News
  • Lupus News
  • Osteoarthritis News
  • Osteoporosis News
  • Psoriatic Arthritis News
  • Rheumatoid Arthritis News
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy